PROTEOMICS - Clinical Applications

Cover image for Vol. 10 Issue 8

Editor-in-Chief: Lorna Stimson, Deputy Editor: Lucie Kalvodova

Impact Factor: 2.959

ISI Journal Citation Reports © Ranking: 2015: 28/77 (BIOCHEMICAL RESEARCH METHODS)

Online ISSN: 1862-8354

Associated Title(s): PROTEOMICS

Virtual Issue on Cancer Proteomics - Body Fluids

The drive for "individualised" medicine recognises the need to treat each patient on an individual basis rather than just on a generic disease basis. Also termed, "personalised" or "stratified" medicine the concept highlights the real need for more biomarkers and nowhere is this more apparent than in cancer. Markers of all types are needed ranging from screening/diagnostic markers to enable earlier intervention, monitoring markers to detect relapse or response to therapy, prognostic markers to optimise treatment and follow-up regimens, and predictive markers to allow selection of the optimal treatment on an individual basis, particularly important given the many targeted therapies now available. Clinical proteomics has the potential to really contribute to the biomarker discovery process, and also in defining or streamlining new therapeutic targets from identifying key factors implicated mechanistically in the underlying disease process. In this virtual issue we have assembled recently published articles from Proteomics Clinical Applications which illustrate the diverse proteomic approaches being taken across many cancer types, focusing on analysis of body fluids, in the drive to deliver findings which may ultimately translate to the clinic.



Findeisen P, Neumaier M
Functional protease profiling for diagnosis of malignant disease
Proteomics Clin Appl. 2012 Feb;6(1-2):60-79.

Rodriguez H, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Boja E
Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective
Proteomics Clin Appl. 2010 Dec;4(12):904-514.

Peracaula R, Sarrats A, Rudd PM
Liver proteins as sensor of human malignancies and inflammation
Proteomics Clin Appl. 2010 Apr;4(4):426-431.


Egler RA, Li Y, Dang TA, Peters TL, Leung E, Huang S, Russell HV, Liu H, Man TK
An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring
Proteomics Clin Appl. 2011 Oct;5(9-10):532-541.

Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND, Wallace DM, Johnson PJ, Zeegers MP, Cheng KK, Martin A, Ward DG
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer
Proteomics Clin Appl. 2011 Oct;5(9-10):493-503.

Tracy MB, Cooke WE, Gatlin CL, Cazares LH, Weaver DM, Semmes OJ, Tracy ER, Manos DM, Malyarenko DI
Improved signal processing and normalization for biomarker protein detection in broad-mass-range TOF mass spectra from clinical samples
Proteomics Clin Appl. 2011 Aug;5(7-8):440-447.

Moshkovskii SA, Sokolova EE, Brattseva EV, Karpova MA, Pyatnitskiy MA, Kubanova AA, Archakov AI
Proteome and cytokine serum profiling to diagnose a mycosis fungoides
Proteomics Clin Appl. 2011 Aug;5(7-8):432-439.

Husi H, Stephens N, Cronshaw A, MacDonald A, Gallagher I, Greig C, Fearon KC, Ross JA
Proteomic analysis of urinary upper gastrointestinal cancer markers
Proteomics Clin Appl. 2011 Jun;5(5-6):289-299.

Høgdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, Engelholm SA, Risum S, Petri AL, Lundvall L, Lomas L, Høgdall C
Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients
Proteomics Clin Appl. 2010 Dec;4(12):940-952.

van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, Beijnen JH
The absolute quantification of eight inter-?-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients
Proteomics Clin Appl. 2010 Dec;4(12):931-939.

Wiesner C, Hannum C, Reckamp K, Figlin R, Dubridge R, Roy SM, Lin S, Becker CH, Jones T, Hiller J, Cheville JC, Wilson K
Consistency of a two clinical site sample collection: a proteomics study
Proteomics Clin Appl. 2010 Sep;4(8-9):726-738.

Paulo JA, Lee LS, Wu B, Repas K, Banks PA, Conwell DL, Steen H
Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS
Proteomics Clin Appl. 2010 Sep;4(8-9):715-725.

Vafadar-Isfahani B, Laversin SA, Ahmad M, Ball G, Coveney C, Lemetre C, Kathleen Miles A, van Schalkwyk G, Rees R, Matharoo-Ball B
Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model
Proteomics Clin Appl. 2010 Sep;4(8-9):682-696.

Rodenburg W, Pennings JL, van Oostrom CT, Roodbergen M, Kuiper RV, Luijten M, de Vries A
Identification of breast cancer biomarkers in transgenic mouse models: A proteomics approach
Proteomics Clin Appl. 2010 Jul;4(6-7):603-612.

Carlsson A, Persson O, Ingvarsson J, Widegren B, Salford L, Borrebaeck CA, Wingren C
Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients
Proteomics Clin Appl. 2010 Jul;4(6-7):591-602.

Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, Struwe WB, de Llorens R, Rudd PM, Peracaula R
Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis
Proteomics Clin Appl. 2010 Apr;4(4):432-448.

Petri AL, Simonsen AH, Høgdall E, Christensen IJ, Kjaer SK, Yip C, Risum S, Pedersen AT, Hartwell D, Fung ET, Høgdall C
Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis
Proteomics Clin Appl. 2010 Mar;4(3):304-314.


Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG
Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer
Proteomics Clin Appl. 2011 Apr;5(3-4):179-188.